Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1). Issue 5 (5th May 2022)

• Record Type: Journal Article
• Authors: Hess, Patrick P.; Ventura Ferreira, Monica S.; Rolles, Benjamin; Kirschner, Martin; Holtbernd, Florian; Tometten, Mareike; Brümmendorf, Tim H.; Beier, Fabian
• Is Part Of: Clinical case reports. Volume 10:Issue 5(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-05-05
• Subjects: hematology -- Hodgkin -- lymphoma -- neurology -- neuropathy; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.5766
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Treatment for Hodgkin lymphoma (HL) in adults comprises substantial risk of chemotherapy‐induced peripheral neurotoxicity. Here, we describe the case of patient with Charcot–Marie–Tooth disease or HSMN1 and advanced Hodgkin lymphoma undergoing treatment with modified BEACOPP achieving complete remission without major aggravation of neurological symptoms. Abstract : Patients with Charcot–Marie–Tooth disease or HSMN1 and advanced Hodgkin lymphoma can be successfully treated with modified BEACOPP achieving complete remission without major aggravation of neurological symptoms.